Analyst Ratings For Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
Today, Laidlaw initiated coverage on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) with a Buy with a price target of $23.00.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) is Buy with a consensus target price of $24.00 per share, a potential 98.02% upside.
Some recent analyst ratings include
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target
- 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Overweight rating
Recent Trading Activity for Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
Shares of Aridis Pharmaceuticals Inc closed the previous trading session at 12.12 −1.18 8.87% with 13.46 shares trading hands.